삼성바이오, 스위스 제약사와 바이오의약품 생산 수주 계약<br /><br />Samsung BioLogics says it has signed a statement of intent for biomedicine contract manufacturing with a Swiss-based pharmaceutical company.<br />The deal is worth over 36-million U.S. dollars.<br />Not much is known about it because of the confidentiality obligation in management,... but details like the other party or the term of a contract will be disclosed in 2024.<br />However, we do know that production will be done at Samsung BioLogics' third plant in Songdo, west of Seoul.<br />On top of that, the current figure is a fixed minimum and could rise to 400-million dollars if certain conditions are met in the future.<br />
